Investors

Press Releases

Press releases issued by Palatin are accessible below. These press releases contain additional information about our business, clinical trial developments, research and development activities, financial achievements, and strategic partnerships.

Investors

Press Releases

Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update

Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025

Palatin Technologies Announces Closing of Reduced Public Offering

Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice

Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice

Palatin Technologies Announces Pricing of up to $23 Million Public Offering

Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy

Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide